Answers are grounded in this paper and cite their sources.
Study updates treatment recommendations for operable breast cancer, suggesting new guidelines due to evolving data.
Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
No takes yet. Share an insight, caveat, or question.
Kaufmann et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: